More Needs To Be Done To Accelerate Device Reviews – von Eschenbach
This article was originally published in The Gray Sheet
Executive Summary
Acting FDA Commissioner Andrew von Eschenbach said the agency needs to go beyond the "incremental" improvements it has made in speeding up the review of device premarket applications under the Medical Device User Fee & Modernization Act (MDUFMA)
You may also be interested in...
Ambitious MDUFMA Goals Up For Discussion May 22
Two ambitious but optional FDA performance goals for device premarket reviews will be up for discussion at a public meeting May 22
Ambitious MDUFMA Goals Up For Discussion May 22
Two ambitious but optional FDA performance goals for device premarket reviews will be up for discussion at a public meeting May 22
MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders
FDA should work to improve the process by which companies and the agency negotiate clinical trial designs, several participants argued at the third annual MDUFMA stakeholder meeting Nov. 17